Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 6,552 shares at $23.38 ($153K) on 2025-12-31, disclosed to the SEC on 2026-01-02.
Scheduled sale ($153k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |
| RCUS | SELL | 2025-01-03 | $54K | — | Filing → |